Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Heart Study: Hyperreflective Foci as Early Biomarkers of Response to Intravitreal Aflibercept 8 mg in Treatment-Naive nAMD
ChiCTR2600128124Phase 4Not yet recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Jul 2026
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of aflibercept in exudative macular degeneration, sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoints: Proportion of patients with a decrease in HRF number at week 12 vs baseline, Proportion of patients with stable HRF number at week 12 vs baseline and 1 more. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
aflibercept
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on ChiCTR2600128124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600128124.